

IN THE CLAIMS:

1. (currently amended) A modified Factor VIII cDNA, comprising:
a wild-type factor VIII cDNA,
at least one intron, which has been inserted into at least one location of
the said wild-type factor VIII cDNA, wherein said at least one intron is not a factor VIII
intron; and
a promoter which targets the expression of said modified factor VIII cDNA
to hematopoietic cells.
2. (previously presented) Modified Factor VIII cDNA as claimed in claim 1,
wherein the B-domain of the wild-type factor VIII cDNA has been deleted.
3. (currently amended) Modified Factor VIII cDNA as claimed in claim 1,
wherein said at least one intron is ~~truncated~~ factor IX truncated intron 1.
4. (canceled).
5. (previously presented) Modified Factor VIII cDNA as claimed in claim 1,
wherein said promoter is the human platelet glycoprotein IIb promoter.
6. (previously presented) Modified Factor VIII cDNA as claimed in claim 1,
wherein said at least one intron has been inserted into the wild-type factor VIII cDNA at
the original positions of intron 1 and intron 13 of the genomic Factor VIII DNA.
7. (previously presented) A process for the production of Factor VIII,
comprising:

culturing a cell line under conditions suitable to produce a polypeptide encoded by the modified Factor VIII cDNA as claimed in claim 1; and
recovering said polypeptide from the cell culture medium.

8. (previously presented) Process as claimed in claim 7, wherein the production of Factor VIII is stimulated by an inducer.

9. (previously presented) Process as claimed in claim 8, wherein said inducer is phorbol-12-myristate-13-acetate.

10. (currently amended) Modified Factor VIII cDNA as claimed in claim 1, wherein said hematopoietic cells are megakaryocytes ~~platelets~~.

11. (currently amended) Process as claimed in claim 7, wherein said cell line is human erythroleukemia (HEL) or Dami.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com